---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-030839"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2025-04-02T23:59:59+00:00"
generated_at: "2026-05-23T23:49:38.768824+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Edgewise reports positive Phase 2 data for EDG-7500 in HCM; 71% LVOT-G reduction at rest

## Summary
- Obstructive HCM: 100 mg dose achieved mean 71% reduction in resting LVOT-G and 58% in provokable gradients over 4 weeks.
- NT-proBNP reduced 62% in obstructive and 42% in nonobstructive HCM at 100 mg; KCCQ-OSS improved 23 and 17 points respectively.
- No LVEF <50%; two participants had serious AF requiring cardioversion; one discontinuation due to dizziness.
- Part D 12-week data expected H2 2025; Phase 3 CIRRUS-HCM trial initiation planned for H1 2026.

## SEC filing metadata
- accession: 0001104659-25-030839
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2025-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465925030839/0001104659-25-030839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465925030839/tm2510984d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-030839
- JSON: https://secwatch.observer/filing/0001104659-25-030839.json
- Plain text: https://secwatch.observer/filing/0001104659-25-030839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.